Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012., Int J Cancer, 136, E359, 10.1002/ijc.29210
Wagner, 2010, Chemotherapy for advanced gastric cancer., Cochrane Database Syst Rev, CD004064
Lordick, 2017, New agents on the horizon in gastric cancer., Ann Oncol, 28, 1767, 10.1093/annonc/mdx051
Smyth, 2016, Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., Ann Oncol, 27, v38, 10.1093/annonc/mdw350
Cancer Genome Atlas Research Network, 2014, Comprehensive molecular characterization of gastric adenocarcinoma., Nature, 513, 202, 10.1038/nature13480
Abdel-Rahman, 2016, Immune checkpoints aberrations and gastric cancer: assessment of prognostic value and evaluation of therapeutic potentials., Crit Rev Oncol Hematol, 97, 65, 10.1016/j.critrevonc.2015.08.015
Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation., J Exp Med, 192, 1027, 10.1084/jem.192.7.1027
Muro, 2016, Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial., Lancet Oncol, 17, 717, 10.1016/S1470-2045(16)00175-3
Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria., Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624
Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors., J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205
Clopper, 1934, The use of confidence or fiducial limits illustrated in the case of binomial., Biometrika, 26, 404, 10.1093/biomet/26.4.404
Wallden, 2016, Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System., J Clin Oncol, 34, 3034, 10.1200/JCO.2016.34.15_suppl.3034
Ayers, 2017, IFN-?-related mRNA profile predicts clinical response to PD-1 blockade., J Clin Invest, 127, 2930, 10.1172/JCI91190
Ribas, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial., Lancet Oncol, 16, 908, 10.1016/S1470-2045(15)00083-2
Nanda, 2016, Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study., J Clin Oncol, 34, 2460, 10.1200/JCO.2015.64.8931
Goldberg, 2016, Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial., Lancet Oncol, 17, 976, 10.1016/S1470-2045(16)30053-5
Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial., Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7
Plimack, 2017, Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study., Lancet Oncol, 18, 212, 10.1016/S1470-2045(17)30007-4
Hamid, 2014, Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL)., J Clin Oncol, 32, 3000, 10.1200/jco.2014.32.15_suppl.3000
Seiwert, 2016, Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial., Lancet Oncol, 17, 956, 10.1016/S1470-2045(16)30066-3
Thuss-Patience, 2011, Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)., Eur J Cancer, 47, 2306, 10.1016/j.ejca.2011.06.002
Kang, 2012, Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone., J Clin Oncol, 30, 1513, 10.1200/JCO.2011.39.4585
Ford, 2014, Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial., Lancet Oncol, 15, 78, 10.1016/S1470-2045(13)70549-7
Fuchs, 2014, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD)., Lancet, 383, 31, 10.1016/S0140-6736(13)61719-5
Hironaka, 2013, Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial., J Clin Oncol, 31, 4438, 10.1200/JCO.2012.48.5805
Wilke, 2014, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial., Lancet Oncol, 15, 1224, 10.1016/S1470-2045(14)70420-6
Chan, 2017, Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: a systematic review and meta-analysis., Crit Rev Oncol Hematol, 116, 68, 10.1016/j.critrevonc.2017.05.002
Le, 2016
Kojima, 2016
Chung, 2016
Segal, 2014, A phase I multi-arm dose-expansion study of the anti-programmed cell death-ligand-1 (PD-L1) antibody media4736: preliminary data., Ann Oncol, 25, iv365, 10.1093/annonc/mdu342.11
Kang, 2017
Kang, 2017, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)., Lancet, 390, 2461, 10.1016/S0140-6736(17)31827-5
Derks, 2016, Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers., Oncotarget, 7, 32925, 10.18632/oncotarget.v7i22
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): gastric cancer (version 5.2017). 2017. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed December 5, 2017.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): esophageal and esophagogastric junction cancers (version 4.2107). 2017. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed December 5, 2017.
National Cancer Institute. Common terminology criteria for adverse events v4.0 (CTCAE). 2009. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed December 5, 2017.
National Institutes of Health. A study of pembrolizumab (MK-3475) versus paclitaxel for participants with advanced gastric/gastroesophageal junction adenocarcinoma that progressed after therapy with platinum and fluoropyrimidine (MK-3475-061/KEYNOTE-061). https://clinicaltrials.gov/ct2/show/NCT02370498. Accessed December 5, 2017.
National Institutes of Health. Study of pembrolizumab (MK-3475) as first-line monotherapy and combination therapy for treatment of advanced gastric or gastroesophageal junction adenocarcinoma (MK-3475-062/KEYNOTE-062). https://clinicaltrials.gov/ct2/show/NCT02494583. Accessed December 5, 2017.